iSERA LIFESCIENCES MD, chairman, board of directors and AGM
BSE: 534920IT - SoftwareSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹143.90.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- Differs from the exchange's3,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Differs from the exchange's
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Differs from the exchange's
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- –
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- −0.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,471
iSERA LIFESCIENCES board of directors
At the end of the quarter to Mar 2025, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonGANAPA NARSI REDDYRelated to the promoter
- Managing directorJAYSHREE BABULAL JAIN
- Company Secretary and Compliance OfficerDeepakshi
6 directors3 independent3 executive
- SIVAJI GOPALAM · Employee DirectorIndependent · joined Feb 2022 · 38 months as independent · 1 listed board · 2 committee seats
- GANESH AMIRINENI · Employee DirectorIndependent · joined Feb 2022 · 38 months as independent · 1 listed board · 2 committee seats, 2 as chair
- GANAPA NARSI REDDY · ChairpersonExecutive · joined Feb 2022 · 1 listed board · 2 committee seats
- JITENDRA PRABHAKARA NENEExecutive · joined Oct 2024 · 1 listed board
- JAYSHREE BABULAL JAIN · Managing directorExecutive · joined Aug 2024 · 1 listed board
- VINITA DILIP MODAKIndependent · joined Oct 2024 · 5 months as independent · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- SURESH FATEHLAJI JAIN, left 24 Oct 2024: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 25 Mar 20255 of 5 present2 independent · no day in between
- 24 Mar 20256 of 6 present3 independent · 41 days in between
- 10 Feb 20256 of 6 present3 independent · 88 days in between
- 13 Nov 20246 of 6 present3 independent · 19 days in between
1 earlier meeting
- 24 Oct 20246 of 6 present3 independent
Audit Committee
Chair GANESH AMIRINENI
SIVAJI GOPALAM, GANAPA NARSI REDDY
- 10 Feb 20253 of 3 present3 independent · 56 days in between
- 12 Nov 20243 of 3 present3 independent
Nomination and remuneration committee
Chair GANESH AMIRINENI
SIVAJI GOPALAM, GANAPA NARSI REDDY
- 24 Mar 20253 of 3 present3 independent · 41 days in between
- 12 Nov 20243 of 3 present3 independent
Stakeholders Relationship Committee
Chair GANESH AMIRINENI
SIVAJI GOPALAM, GANAPA NARSI REDDY
- 15 Jan 20253 of 3 present3 independent
- 15 Dec 20243 of 3 present3 independent · 32 days in between
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- GMKS & CoPeer-review certificate valid to Mar 2026
1 earlier auditor
- V Ravi & CoNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
iSERA LIFESCIENCES AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.iSERA LIFESCIENCES dividend history
Annual general meeting, 29 Sep 2026
1,037 shareholders on the register on 22 Sep 2026; present: 0 promoters and 47 others; votes counted by Anuj Gupta / M/s Anuj Gupta & Associates.The company's voting result (opens in a new tab)
To receive, consider and adopt the financial statement of the Company for the year ended 31st March, 2026 including Audited Balance Sheet as at 31st March, 2026 and the Statement of the Profit & Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 9.30% · promoters 0.00% · institutions 0.00% · other public 22.47%
To re-appoint a director in place of of Mr. Jitendra Prabhakar Nene (DIN: 06814833), who retires by rotation at this Annual General Meeting and being eligible, offers herself for reappointment subject to approval of the Shareholders.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 9.30% · promoters 0.00% · institutions 0.00% · other public 22.47%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Rights IssuesNov 2025, checked by Infomarics Valuations and Rating Limited | 8.08 | – | – | No |